Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 44,715,743	$ 35,300,805
Receivable due from collaboration agreement	831,061
Research and development tax incentive receivable	1,111,540
Prepaid assets and other current assets	833,630	2,258,229
Total current assets	47,491,974	37,559,034
Property and equipment, net	1,810,235	1,102,808
Total assets	49,302,209	38,661,842
Current liabilities:
Accounts payable	1,557,612	1,297,725
Deferred research grant revenue		24,315
Total liabilities	1,557,612	1,322,040
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 25,371,781 and 22,534,874 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	25,372	22,535
Additional paid-in capital	103,158,144	71,648,453
Accumulated other comprehensive loss	(170,328)	(51,538)
Accumulated deficit	(55,268,591)	(34,279,648)
Total stockholders’ equity	47,744,597	37,339,802
Total liabilities and stockholders’ equity	$ 49,302,209	$ 38,661,842